5-oxohexanoyl N-hydroxysuccinimide ester | 102674-38-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 5-oxohexanoyl N-hydroxysuccinimide ester
• 英文别名: 2,5-dioxopyrrolidin-1-yl 5-oxohexanoate；hexanoic acid 5-oxo 2,5-dioxo-1-pyrrolidinyl ester；δ-ketohexanoic-N-hydroxysuccinimide ester；(2,5-Dioxopyrrolidin-1-yl) 5-oxohexanoate
• CAS: 102674-38-4
• 化学式: C₁₀H₁₃NO₅
• 分子量: 227.217
• InChiKey: OXOGCNFFTVFWBF-UHFFFAOYSA-N

物化性质

• 沸点：
  361.6±44.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  80.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-oxohexanoyl N-hydroxysuccinimide ester 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.33h， 生成 NOHK
  参考文献：
  名称：

  一种非天然氨基酸及其应用、包含其的重组蛋白以及重组蛋白偶联物

  摘要：

  本发明提供了一种非天然氨基酸，为具有如式(Ⅰ)所示结构的化合物或其对映异构体。本发明还提供了所述非天然氨基酸的应用。进一步地，本发明还提供了一种包含所述非天然氨基酸的重组蛋白以及由所述重组蛋白制得的蛋白偶联物。本发明提供的非天然氨基酸制备简便，安全性好，插入蛋白时不易失活，与偶联部分的结合率高，所得偶联物的稳定性较好，本发明提供的非天然氨基酸可应用于众多领域，尤其是在制备重组蛋白或重组蛋白偶联物中，

  公开号：

  CN113548984B
• 作为产物：
  描述：

  丁位己内酯 在 N,N'-二环己基碳二亚胺 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 44.0h， 生成 5-oxohexanoyl N-hydroxysuccinimide ester
  参考文献：
  名称：

  Insights into β-ketoacyl-chain recognition for β-ketoacyl-ACP utilizing AHL synthases

  摘要：

  报道了用于两种3-氧代酰-ACP利用类群信号合成酶的β-酮酰-ACP模拟物的设计、合成和动力学评价。

  DOI：

  10.1039/c8cc04532a

文献信息

• Method of producing monoclonal auto-anti-idiotypic antibodies
  申请人：The Trustees of Columbia University in the City of New York

  公开号：US05144010A1

  公开（公告）日：1992-09-01

  This invention provides an auto-anti-idiotypic method for producing a monoclonal anti-idiotypic antibody. The method involves contacting lymphoid cells of an animal under suitable conditions with an effective antibody-raising amount of an antigen, collecting the lymphoid cells from the animal at a suitable time after the contacting and fusing the collected lymphoid cells with appropriate myeloma cells to produce a series of hybridoma cells each of which produces a monoclonal antibody. The method further involves screening, under suitable conditions, the series of hybridoma cells so produced to identify those which secrete a monoclonal antibody capable of binding to an antibody directed to the antigen, or to a receptor where the antigen is a ligand to the receptor, separately culturing a hybridoma cell so identified in an appropriate medium, and separately recovering under suitable conditions the monoclonal anti-idiotypic antibody produced by the hybridoma cell.

  这项发明提供了一种用于生产单克隆抗独特型抗体的自动抗独特型方法。该方法涉及在适当条件下将动物的淋巴细胞与有效的抗体诱导剂量的抗原接触，适当时间后从动物收集淋巴细胞，并将收集的淋巴细胞与适当的骨髓瘤细胞融合，以产生一系列每个产生单克隆抗体的杂交瘤细胞。该方法进一步涉及在适当条件下筛选所产生的一系列杂交瘤细胞，以识别那些分泌能够结合到抗原的抗体或者抗原是配体的受体的单克隆抗体的杂交瘤细胞，单独在适当培养基中培养所识别的杂交瘤细胞，并在适当条件下单独回收由杂交瘤细胞产生的单克隆抗独特型抗体。
• [EN] NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE<br/>[FR] NOUVEAUX COMPOSÉS ET CONJUGUÉS DE CRYPTOPHYCINE, LEUR PRÉPARATION ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：SANOFI SA

  公开号：WO2017076998A1

  公开（公告）日：2017-05-11

  The present invention relates to cryptophycin compounds of formula (I). The invention also relates to cryptophycin payloads, to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The invention also relates to the process for preparing these conjugates.

  本发明涉及公式（I）的隐藻素化合物。该发明还涉及隐藻素有效载荷、隐藻素偶联物、含有它们的组合物及其治疗用途，尤其是作为抗癌剂。该发明还涉及制备这些偶联物的过程。
• [EN] BRANCHED MOIETY FOR USE IN CONJUGATES<br/>[FR] FRACTION RAMIFIÉE DESTINÉE À ÊTRE UTILISÉE DANS DES CONJUGUÉS
  申请人：MEDIMMUNE LLC

  公开号：WO2021080608A1

  公开（公告）日：2021-04-29

  A tri-functional linker moiety: formula (I), where X and Y are linking chains, and its use for preparing dual-mechanistic drug conjugates, preferably in a site-specific manner.

  一种三功能连接物：式（I），其中X和Y是连接链，以及其用于以特定位点方式制备双机制药物结合物的用途。
• NOVEL WATER-SOLUBLE COMPLEXING AGENTS AND CORRESPONDING LANTHANIDE COMPLEXES
  申请人：CISBIO BIOASSAYS

  公开号：US20150361116A1

  公开（公告）日：2015-12-17

  The invention relates to complexing agents of formula (I): in which A, chrom1, chrom2 and chrom3 are as defined in the description. The invention also relates to the lanthanide complexes obtained from these complexing agents.

  该发明涉及公式（I）中的络合剂：其中A、chrom1、chrom2和chrom3如描述中所定义。该发明还涉及从这些络合剂获得的镧系金属络合物。
• Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices
  申请人：Stockman E. Kenneth

  公开号：US20070196454A1

  公开（公告）日：2007-08-23

  One aspect of the present invention generally relates to methods of sealing a wound or tissue plane or filling a void splace. In a preferred embodiment, the wound is an ophthalmic, pleural or dural wound. In certain instances, the compositions used to seal the wound or tissue plane comprises a polyalkyleneamine. In a preferred embodiment, the polyalkyleneamine is polyethyleneimine. Treatment of the polyethyleneimine with a cross-linking reagent causes the polyethyleneimine polymers to polymerize forming a seal. In certain instances, the cross-linking reagent is a polyethylene glycol having reactive terminal groups. In certain instances, the reactive terminal groups are activated esters, such as N-hydroxy succinimide ester. In certain instances, the reactive terminal groups are isocyanates. In certain instances, the polyethyleneimine has a lysine, cysteine, isocysteine or other nucleophilic group attached to the periphery of the polymer. In certain instances, the polyethyleneimine is mixed with a second polymer, such as a polyethylene glycol containing nucleophilic groups. In certain instances, the compositions used to seal the wound or tissue plane are formed by reacting a polyalkyleneamine bearing electrophilic groups with a cross-linking reagent containing nucleophilic groups. In certain instances, the electrophilic groups on the polyalkyleneamine are activated esters, such as N-hydroxy succinimide ester. In certain instances, the compositions used to seal the wound or tissue plane are formed by reacting a polyalkyleneamine bearing photopolymerizable groups with ultraviolet or visibile light. Compositions used to seal the wound which contain PEI or a derivative of PEI are found to adhere tightly to the tissue. Other aspects of the present invention relate to methods of filling a void of a patient or adhering tissue. In certain instances, the methods use a polyalkyleneamine. In a preferred embodiment, the polyalkyleneamine is polyethyleneimine. Another aspect of the present invention relates to a polymeric composition formed by exposing a polyalkyleneamine to an activated polyalkylene glycol. In certain instances, the composition is attached to mammalian tissue.

  本发明的一个方面通常涉及封闭伤口或组织平面或填充空隙的方法。在一个优选实施例中，伤口是眼科、胸膜或硬脑膜伤口。在某些情况下，用于封闭伤口或组织平面的组合物包括聚烷胺。在一个优选实施例中，聚烷胺是聚乙烯亚胺。用交联试剂处理聚乙烯亚胺会导致聚乙烯亚胺聚合物聚合形成密封。在某些情况下，交联试剂是具有反应末端基团的聚乙二醇。在某些情况下，反应末端基团是活化酯，如N-羟基琥珀酰亚胺酯。在某些情况下，反应末端基团是异氰酸酯。在某些情况下，聚乙烯亚胺具有赖氨酸、半胱氨酸、异半胱氨酸或其他亲核基团附着在聚合物的周边。在某些情况下，聚乙烯亚胺与第二聚合物混合，如含有亲核基团的聚乙二醇。在某些情况下，用于封闭伤口或组织平面的组合物是通过将具有亲电子基团的聚烷胺与含有亲核基团的交联试剂反应形成的。在某些情况下，聚烷胺上的亲电子基团是活化酯，如N-羟基琥珀酰亚胺酯。在某些情况下，用于封闭伤口或组织平面的组合物是通过将具有光聚合基团的聚烷胺与紫外光或可见光反应形成的。发现含有PEI或PEI衍生物的用于封闭伤口的组合物能够紧密粘附在组织上。本发明的其他方面涉及填充患者空隙或粘附组织的方法。在某些情况下，这些方法使用聚烷胺。在一个优选实施例中，聚烷胺是聚乙烯亚胺。本发明的另一个方面涉及通过将聚烷胺暴露于活化聚乙烯醇而形成的聚合物组合物。在某些情况下，这种组合物附着在哺乳动物组织上。